Zacks Bull and Bear of the Day Highlights: Salix Pharmaceuticals, Integra LifeSciences, Tesla Motors, Nissan Motor and Toyota Motor

Zacks

For Immediate Release

Chicago, IL – June 3, 2013 – Zacks Equity Research highlights Salix Pharmaceuticals (SLXP) as the Bull of the Day and Integra LifeSciences (IART) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Tesla Motors Inc. (TSLA), Nissan Motor (NSANY) and Toyota Motor (TM).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.

Here is a synopsis of all five stocks:

Bull of the Day:

The world of pharmaceutical companies is filled with many diverse product niches, scientific disciplines, and business models. Salix Pharmaceuticals (SLXP) is a uniquely focused and profit-growing company that specializes in finding, developing, and marketing high-potential gastrointestinal disease products.

And the Salix growth story just got a boost recently when analysts raised estimates and price targets after the company reported solid first quarter results and reiterated its guidance of $920 million in revenues and non-GAAP EPS of $3.37 for 2013.

Below is a look at the price breakout to new all-time highs above $56 after their May 9 report. As analysts reacted, the stock became a Zacks #2 Rank (Buy) on May 14 and then a Zacks #1 Rank (Strong Buy) on May 15 before it powered through $60 and hit new highs last Friday at $62.10.

Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the company's gastroenterology specialty sales and marketing team.

Their flagship prescription drug Xifaxan brought in $153 million in sales vs. total revenues of $202 million for the quarter.

Bear of the Day:

I look at a lot of medical and healthcare stocks because as an investor-trader with time frames of one month to one decade, the future of medicine is where some of the biggest opportunities are.

And even though two Zacks industries covering over 250 "biopharma" companies have led the market advance this year, there are definitely some underperformers in these groups as well.

Integra LifeSciences (IART) is a $1 billion medical device and implant company that has been a Zacks #4 Rank (Sell) since early January when it was trading above $40.

Then after revealing a series of product recalls in April, the stock fell from $38 to $31. But it made quite a bounce in May even in the face of continued analyst downgrades to its earnings outlook, getting all the way back to $38 to "fill the gap" as chartists like to say.

 

Integra makes specialized products for numerous types of surgical procedures, from extremity and spinal reconstruction to major burn treatment and neurosurgeries.

On April 10, the company initiated a voluntary recall of some of its products manufactured during Dec 2010-May 2011 and Nov 2012-Mar 2013 at its Anyasco, Puerto Rico facility.

 Latest Posts on the Zacks Analyst Blog:

Tesla Surprises, Boosts Supercharging Stations

Tesla Motors Inc. (TSLA) is full of surprises! The electric carmaker announced that it will add more supercharging stations across the U.S., which are 10 times faster than the ordinary public charging stations, so that its Model S owners can travel across the country without worrying about the batter driving range.

The company plans to increase the number of charging stations threefold from 9 to 27 by the end of next month, which could further rise to 100 by the end of next year.

Electric cars have always been criticized for limited driving range leading to their weak demand. This led to limiting sales of vehicles such as Nissan Motor’s (NSANY) Leaf and Toyota Motor’s (TM) plug-in Prius.

Compared to its counterparts, Tesla’s Model S has a relatively longer driving range. The vehicle can travel 208 miles per charge for about three hours in normal driving conditions while its top-end model can travel about 265 miles in a single charge.

However, with the expanded supercharging network, owners of Model S sedan can make long-distance trips without any hassle since the network can recharge the battery to 50% of its capacity in 20 to 30 minutes. With further improvements in technology, Tesla will reduce the time to fully recharge the battery nearly half to 20 minutes. The new technology is in beta version now. It will allow the Model S to be charged at 120 kW, up from 90 kW previously.

Currently, Tesla has 8 supercharger stations in California and on the East Coast. The company plans to add four stations in California this summer, so that by fall this year; it should have charging stations in most metro areas.

By 2014, Tesla plans to install charging stations within reach of 80% of people in the U.S. and Canada, and 98% by 2015. With this, the company intends to provide supercharging stations every 80 to 100 miles.

The company revealed that the average cost per station, is roughly $150,000 in capital expenditures, without solar. An additional $150,000 will be required with the solar charging; pushing each station’s cost to roughly $300,000.

Currently, all Model S vehicles (size comparable to an Audi A6 or the BMW 5 series) have supercharger capabilities with the 85 KwH battery pack. It also has an optional 60 kwH battery pack. They are priced around $70,000. However, the company expects to launch more affordable electric cars in 3 to 4 years in a $30,000 to $40,000 range, which will probably be smaller than Model S.

Recently, Tesla paid off the remaining $465 million U.S. Department of Energy (:DOE) loan much earlier than expected. The electric carmaker received the loan in Jan 2010 and agreed on a 10-year repayment program. However, the situation became so much favorable that the company repaid the full outstanding amount of the loan in the second installment itself.

Last December, Tesla made its first DOE loan repayment of nearly $13 million. On May 22, the company paid off the remaining $451.8 million using the near-$1 billion proceeds from the common stock and convertible senior note offering made last week.

Tesla’s share prices started soaring following the reports of its first-ever quarterly profit on May 8 and early loan repayment. On May 29, Tesla shares hit new 52-week high of $114.90, which is above its previous level of $110.75 a day before. Their last closing price of $104.95 represented a whopping one-year return of 277.8% and solid year-to-date return of 224.9%. The company has a market cap of $12.0 billion.

In 2012, Tesla lost $396.2 million or $3.69 per share compared with $254.4 million or $2.53 per share in 2011. Due to a good start in 2013, the company had expected to repay its DOE loan much earlier and boost production of vehicles to lower production cost.

Tesla reported its first-ever quarterly profit of $15.4 million, or 12 cents per share (on an adjusted basis) in the first quarter of 2013 compared with a loss of $79.3 million or 76 cents in the corresponding quarter of 2012. This indicated a whopping positive earnings surprise of 271.4% given the Zacks Consensus Estimate of a loss of 7 cents for the quarter.

Revenues jumped manifold to $561.8 million from $30.2 million in the first quarter of 2012. Thanks to the impressive 5,000 units of Model S electric car sales during the quarter.

Tesla expects to manufacture 5,000 Model S vehicles in the second quarter of the year. For full year 2013, the company expects to deliver 21,000 Model S cars globally, up 5% from its prior guidance of 20,000 units.

Shares of Tesla retain a Zacks Rank #3, which implies a short-term (one to three months) Hold rating.

 

Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Read the analyst report on SLXP

Read the analyst report on IART

Read the analyst report on TSLA

Read the analyst report on NSANY

Read the analyst report on TM

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)